Abstract Onco-Profiling and Immuno-Profiling: The New Age of Precision Cancer Medicine
by Dr Jan Mou Lee

Since dysregulation of the immune system is frequently observed in patients with solid tumors and autoimmune disorders, evaluating changes in the immune cell profile can support physicians in prescribing more precisely. Regarding precision diagnosis, FullHope Biomedical Co., Ltd. (FHB) provides Immunoprofiling (IP) and Circulating Tumor Cells Testing (CTC), which track changes in the immune system and the phenotypes of circulating tumor cells (e.g., mutant EGFR, VEGFR1-3, and PD-L1) via flow cytometry and epitope-specific monoclonal antibodies. Based on the information from IP and CTC, physicians can help patients assess the risk of suffering from immune-related diseases.

For patients with solid tumors or immune-related tumors, physicians can estimate the effectiveness of immunotherapies (such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy [ACT]) and customize medication tailored to their needs. In addition to precision diagnosis, FHB also develops several pipelines in regenerative medicine, including one-stop cultivation techniques for tumor-specific T cells, antibody-conjugated immune effector cells, adipose-derived mesenchymal stem cells, and immune-effector-cell-derived exosomes, which can customize the production of regenerative medicine products to address different clinical needs.